| Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations KT Flaherty, JR Infante, A Daud, R Gonzalez, RF Kefford, J Sosman, ... New England Journal of Medicine 367 (18), 1694-1703, 2012 | 3086 | 2012 |
| Talimogene laherparepvec improves durable response rate in patients with advanced melanoma RHI Andtbacka, HL Kaufman, F Collichio, T Amatruda, N Senzer, ... Journal of clinical oncology 33 (25), 2780-2788, 2015 | 2569 | 2015 |
| Survival in BRAF V600–mutant advanced melanoma treated with vemurafenib JA Sosman, KB Kim, L Schuchter, R Gonzalez, AC Pavlick, JS Weber, ... New England Journal of Medicine 366 (8), 707-714, 2012 | 2564 | 2012 |
| Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial A Ribas, I Puzanov, R Dummer, D Schadendorf, O Hamid, C Robert, ... The lancet oncology 16 (8), 908-918, 2015 | 1754 | 2015 |
| Efficacy and safety of vismodegib in advanced basal-cell carcinoma A Sekulic, MR Migden, AE Oro, L Dirix, KD Lewis, JD Hainsworth, ... New England Journal of Medicine 366 (23), 2171-2179, 2012 | 1616 | 2012 |
| Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial HL Kaufman, J Russell, O Hamid, S Bhatia, P Terheyden, SP D'Angelo, ... The lancet oncology 17 (10), 1374-1385, 2016 | 1277 | 2016 |
| PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma MR Migden, D Rischin, CD Schmults, A Guminski, A Hauschild, KD Lewis, ... New England Journal of Medicine 379 (4), 341-351, 2018 | 1261 | 2018 |
| Combined nivolumab and ipilimumab in melanoma metastatic to the brain HA Tawbi, PA Forsyth, A Algazi, O Hamid, FS Hodi, SJ Moschos, ... New England Journal of Medicine 379 (8), 722-730, 2018 | 1168 | 2018 |
| Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial GS Falchook, KD Lewis, JR Infante, MS Gordon, NJ Vogelzang, ... The lancet oncology 13 (8), 782-789, 2012 | 592 | 2012 |
| Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the … R Gutzmer, D Stroyakovskiy, H Gogas, C Robert, K Lewis, S Protsenko, ... The Lancet 395 (10240), 1835-1844, 2020 | 570 | 2020 |
| Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor KB Kim, R Kefford, AC Pavlick, JR Infante, A Ribas, JA Sosman, ... Journal of Clinical Oncology 31 (4), 482, 2013 | 550 | 2013 |
| Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma K Trunzer, AC Pavlick, L Schuchter, R Gonzalez, GA McArthur, TE Hutson, ... Journal of clinical oncology 31 (14), 1767-1774, 2013 | 463 | 2013 |
| Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial RD Carvajal, JA Sosman, JF Quevedo, MM Milhem, AM Joshua, ... Jama 311 (23), 2397-2405, 2014 | 449 | 2014 |
| Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial MR Migden, A Guminski, R Gutzmer, L Dirix, KD Lewis, P Combemale, ... The Lancet Oncology 16 (6), 716-728, 2015 | 441 | 2015 |
| Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial MR Migden, NI Khushalani, ALS Chang, KD Lewis, CD Schmults, ... The lancet oncology 21 (2), 294-305, 2020 | 375 | 2020 |
| Overall Survival and Durable Responses in Patients With BRAF V600–Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib GV Long, JS Weber, JR Infante, KB Kim, A Daud, R Gonzalez, JA Sosman, ... Journal of Clinical Oncology 34 (8), 871-878, 2016 | 331 | 2016 |
| Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after≥ 1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial HL Kaufman, JS Russell, O Hamid, S Bhatia, P Terheyden, SP D’Angelo, ... Journal for immunotherapy of cancer 6, 1-7, 2018 | 321 | 2018 |
| Basal cell skin cancer, version 1.2016, NCCN clinical practice guidelines in oncology CK Bichakjian, T Olencki, SZ Aasi, M Alam, JS Andersen, D Berg, ... Journal of the National Comprehensive Cancer Network 14 (5), 574-597, 2016 | 314 | 2016 |
| Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study A Ribas, R Gonzalez, A Pavlick, O Hamid, TF Gajewski, A Daud, ... The lancet oncology 15 (9), 954-965, 2014 | 304 | 2014 |
| Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group DF McDermott, JA Sosman, R Gonzalez, FS Hodi, GP Linette, J Richards, ... Journal of Clinical Oncology 26 (13), 2178-2185, 2008 | 298 | 2008 |
